47 results
SC 14D9/A
STSA
Satsuma Pharmaceuticals Inc
30 May 23
Tender offer solicitation (amended)
9:42pm
are not named as parties to the lawsuits. The above-referenced actions are collectively referred to as the “Tender Offer Litigation.”
As of the filing … in the Statement be disclosed, and one books and records demand letter (collectively, the “Demands,” and together with the Tender Offer Litigation
SC 14D9
STSA
Satsuma Pharmaceuticals Inc
5 May 23
Tender offer solicitation
8:17am
substantial expenses related to the Offer and the Merger, including in connection with any litigation that may arise in the future, and the effect … not undertake any independent analysis of any potential or actual litigation, regulatory action, possible unasserted claims or other contingent liabilities
SC14D9C
STSA
Satsuma Pharmaceuticals Inc
17 Apr 23
Written communication relating to third party tender offer
4:02pm
harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements may be identified … ; and the risk that shareholder litigation in connection with the offer or the merger may result in significant costs of defense, indemnification and liability
8-K
EX-2.2
STSA
Satsuma Pharmaceuticals Inc
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
as provided hereunder.
5.5 Absence of Litigation. As of the date hereof, there is no Legal Proceeding pending against, or, to the knowledge … RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT
8-K
EX-99.1
6v28 75qgw06m36n
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
8-K
EX-2.1
9fu7g603tm9zh xsda
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
8-K
4g1xbua q4471qcjrs
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
424B5
bc4ytq k3v4
3 Nov 22
Prospectus supplement for primary offering
4:42pm
424B3
382t7cr7tym6ok
6 May 21
Prospectus supplement
12:00am